Inventor · disambiguated record
Sophie Perrin-Ninkovic
Also filed as: PERRIN-NINKOVIC SOPHIE
18 granted patents·1 pending application·311 citations·filing 2003–2022
94Inventor score
Files withSIGNAL PHARM LLC12PERRIN-NINKOVIC SOPHIE3CELGENE CORP2HARRIS ROY L1SIGNAL PHARMACEUTICAL LLC1
Top patents by PatentIndex Score
19 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0296US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0396US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0495US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0593US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 0691US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 0788US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 0884US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 0984US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
- 1080US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 1180US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 1277US7358274B2Methods for treating or preventing cancer using Benzopyranone CompoundsSIGNAL PHARM LLC·Filed 2006·Granted Apr 15, 2008·2 cites·11 claims
- 1374US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 1473US7091235B2Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancerSIGNAL PHARM LLC·Filed 2003·Granted Aug 15, 2006·5 cites·11 claims
- 1572US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 1670US9193692B2Halogen substituted pyrazines as intermediates of mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Granted Nov 24, 2015·0 cites·14 claims
- 1768US12486281B2Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Dec 2, 2025·0 cites·25 claims
- 1861US7589119B2Methods for treating or preventing metastatic cancer using benzopyranone compoundsSIGNAL PHARMACEUTICAL LLC·Filed 2008·Granted Sep 15, 2009·0 cites·14 claims
- 1959US11306101B2Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2020·Granted Apr 19, 2022·0 cites·35 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →